Sun Pharmaceutical Industries Ltd

SUNPHARMA.NS · Health Technology · Pharmaceuticals: Major · IN

38,000 employees · sunpharma.com

About

Sun Pharmaceutical Industries Ltd is a leading company in the pharmaceutical industry, with its headquarters in Mumbai. The company was founded in 1983 by Dilip Shanghvi, a pharmacist who started with a capital of only 2000 rupees. The company's history began with the manufacturing of psychotropic drugs. However, Sun Pharma quickly expanded into other areas, including dermatology, cardiology, pain medicine, and oncology. Over the years, the company has acquired many companies and established itself in the pharmaceutical industry through mergers and acquisitions. It has a market presence in the USA, Europe, Japan, Australia, and Africa. Sun Pharmaceutical Industries Ltd's business model is based on the development and manufacturing of pharmaceuticals, generics, and biosimilars, as well as the provision of healthcare services. The company aims to provide innovative and affordable medicines to patients worldwide. Sun Pharma is divided into various segments, including generic drug manufacturing, specialty pharmaceuticals, and its own developed oncology platform. In the generic drug manufacturing, Sun Pharma is considered one of the world's largest suppliers, covering a wide range of therapeutic areas. One of its most well-known segments is the manufacturing of nerve blockers and painkillers. In fact, Sun Pharma was the first Indian corporation to receive approval for an opioid painkiller in the United States. Sun Pharmaceutical Industries Ltd offers a wide range of products, including: 1. Generics: The company is known for its cost-effective and high-quality generics, providing affordable treatment for a variety of diseases. 2. Biosimilars: Sun Pharma is also involved in the manufacturing of biosimilars, which has proven to be an important area. 3. Specialty pharmaceuticals: This segment includes a wide range of specialty pharmaceuticals, including medications for diabetes, asthma, and HIV treatment. 4. Oncology platform: Sun Pharma is focused on developing and marketing a wide range of oncology products, including cytostatics, immunotherapeutics, and cancer treatments. Sun Pharmaceutical Industries Ltd has a wide network of research and development facilities in India and around the world. The company has acquired numerous patents and licenses to develop and market innovative drugs. A particular capability lies in developing complex technologies and techniques to offer cost-effective therapies. In the past, Sun Pharma has faced some controversies, particularly related to the trading of opioids in the USA. However, the company has overcome these challenges and continues to focus on providing affordable and innovative medicines. In summary, Sun Pharmaceutical Industries Ltd is a leading company in the pharmaceutical industry. With a wide range of products and services and a global presence, it is a significant player in the global market. The company remains dedicated to developing innovative and affordable drugs to meet the needs of patients worldwide.

Annual results

Reported figures, INR · revenue up 10.7% in 2026

YearRevenueNet incomeNet marginFree cash flow
2026582B115B19.7%—
2025526B109B20.8%—
2024485B95.8B19.7%—
2023439B84.7B19.3%—
2022387B32.7B8.5%—

Dividends per share

2026 16.00 INR2025 16.00 INR2024 13.50 INR2023 11.50 INR2022 10.00 INR

SUNPHARMA.NS in MarketPulse

The live chart with RSI and moving averages, the price, news, signals and price alerts for Sun Pharmaceutical Industries Ltd are inside MarketPulse — currently in private beta.

Company data by Eulerpool. Logos provided by Elbstream. Reported figures, not investment advice.

Sun Pharmaceutical Industries Ltd (SUNPHARMA.NS) — company profile and financials · MarketPulse